Open Access

5HT2A polymorphism His452Tyr in a German Caucasian systemic sclerosis population

  • Holger Kirsten1, 2, 3,
  • Jana Burkhardt1,
  • Helene Hantmann2,
  • Nico Hunzelmann4,
  • Peter Vaith5,
  • Peter Ahnert1, 6 and
  • Inga Melchers7Email author
Contributed equally
Arthritis Research & Therapy200911:403

https://doi.org/10.1186/ar2606

Published: 26 March 2009

Recently, Beretta and colleagues [1] reported a protective association of the serotonin 5-HT2A receptor gene polymorphism His452Tyr (C+1354T, rs6314) with systemic sclerosis (SSc) in an Italian population. 5HT2A accounts for most vasoconstrictive and platelet aggregation due to serotonin activity [2]. Beretta and colleagues also demonstrated that plasma from healthy heterozygous carriers of His452Tyr showed decreased platelet aggregation after serotonin stimulus compared to plasma from healthy individuals homozygous for His452. In consequence, they suggested a functional role of His452Tyr in reducing susceptibility to SSc.

We performed a population-based replication study in an independent and larger German Caucasian SSc cohort, approved by local ethics committees. DNA was purified from blood samples after obtaining written informed consent. Patients were included according to the German Network for Systemic Scleroderma guidelines [3]. The patient cohort was characterised as follows [4]: all fulfilled minimal requirements of LeRoy and colleagues [5] and 81% fulfilled ACR criteria [6]; 80% were females, 50% presented with the limited cutaneous form (lSSc [3]), 33% with the diffuse cutaneous form (dSSc [3]), 89% carried antinuclear antibodies (ANA-positive), 43% anticentromere antibodies (ACA-positive), 39% antitopoisomerase I antibodies (ATA-positive), and they had a mean age of disease onset of 49.5 ± 13.8 years. Mass spectrometry-based genotyping was applied as described, with minor modifications [4]. Power was >96% to replicate the allelic association and >99% to replicate a decreased minor allele frequency within cases [7], as reported for the Italian population.

HapMap data reveal considerable variation of Tyr452 frequency among populations. It is especially high within Africans, emphasizing the importance of appropriate case-control matching. The frequency in our controls was very similar to that in the Caucasian HapMap cohort (0.065 versus 0.063, respectively). It was higher in the Italian population (0.124).

We did not find a protective association of His452Tyr with SSc. In contrast, the frequency of Tyr452 was not decreased, but even increased in all SSc patients (Table 1). Also, no association was found when SSc subgroups stratified for the fulfilment of ACR-criteria, clinical classification (lSSc, dSSc), autoantibody status (ANA-, ACA-, ATA-positive) or sex were compared to healthy donors. However, Tyr452-positive SSc patients were less frequently dSSc positive than His452 homozygous SSc patients (P = 0.048, 9% versus 20%, respectively). This might indicate that the 5HT2A polymorphism may influence the severity of SSc.
Table 1

Distribution of C+1354T within German systemic sclerosis patients and controls

 

Genotype

C versus T

 

CC

CT

TT

Total

MAF

OR (95%CI)

P a

Patients

176

31

2

209

0.084

1.32 (0.8–2.2)

0.28

Controls

203

28

1

232

0.065

  

aP-values were calculated with Fisher's exact test. Genotypes in cases and controls were consistent with Hardy-Weinberg equilibrium. Frequencies of genotypes were also not significantly different between patients and controls (P = 0.52, exact Fisher Freeman Halton test). CI, confidence interval; MAF, minor allele frequency; OR, odds ratio.

In summary, we could not replicate an association of the 5HT2A His452Tyr polymorphism with SSc in a larger German Caucasian cohort. However, an influence of this single nucleotide polymorphism on severity of SSc may exist.

Notes

Abbreviations

SSc: 

systemic sclerosis.

Declarations

Acknowledgements

Support originated from the BMBF ('German Network for Systemic Scleroderma' to IM and NH; 'Hochschul-Wissenschafts-Programm'to PA), the SAB (7692/1187) and EFRE (EFRE4212/04-04) to PA.

Authors’ Affiliations

(1)
Institute of Clinical Immunology and Transfusion Medicine, Center for Biotechnology and Biomedicine (BBZ), University of Leipzig, Johannisallee
(2)
Fraunhofer Institute for Cell Therapy and Immunology
(3)
Translational Center for Regenerative Medicine, University of Leipzig
(4)
Department of Dermatology, University of Cologne
(5)
Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg
(6)
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig
(7)
Clinical Research Unit for Rheumatology, University Medical Center

References

  1. Beretta L, Cossu M, Marchini M, Cappiello F, Artoni A, Motta G, Scorza R: A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation. Arthritis Res Ther. 2008, 10: R103-10.1186/ar2495.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Welsh DJ, Harnett M, MacLean M, Peacock AJ: Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter. Am J Respir Crit Care Med. 2004, 170: 252-259. 10.1164/rccm.200302-264OC.View ArticlePubMedGoogle Scholar
  3. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, Schmidt E, Lehmann P, Foeldvári I, Reichenberger F, et al: The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology. 2008, 47: 1185-1192. 10.1093/rheumatology/ken179.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Kirsten H, Blume M, Emmrich F, Hunzelmann N, Mierau R, Rzepka R, Vaith P, Witte T, Melchers I, Ahnert P: No association between systemic sclerosis and C77G polymorphism in the human PTPRC (CD45) gene. J Rheumatol. 2008, 35: 1817-1819.PubMedGoogle Scholar
  5. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988, 15: 202-205.PubMedGoogle Scholar
  6. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23: 581-590. 10.1002/art.1780230510.View ArticleGoogle Scholar
  7. Garnier S, Dieude P, Michou L, Barbet S, Tan A, Lasbleiz S, Bardin T, Prum B, Cornelis F: IRF5 rs2004640-T allele, the new genetic factor for systemic lupus erythematosus, is not associated with rheumatoid arthritis. Ann Rheum Dis. 2007, 66: 828-831. 10.1136/ard.2006.061390.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© BioMed Central Ltd 2009

Advertisement